Education
About Us
Working with TipRanks
Follow Us
DBV Technologies SA - American (DBVT)
NASDAQ:DBVT
DBVT Stock Chart & Stats
$20.99
$0.34(9.80%)
At close: 4:00 PM EST
$20.99
$0.34(9.80%)
Day’s Range― - ―
52-Week Range$3.82 - $26.19
Previous CloseN/A
Volume52.91K
Average Volume (3M)341.13K
Market Cap
$1.18B
Enterprise Value$679.43M
Total Cash (Recent Filing)$69.84M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.09
Next Earnings
Mar 05, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding55,670,418
10 Day Avg. Volume134,306
30 Day Avg. Volume341,126
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.56
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue1.33K
Enterprise Value/Gross Profit-52.80
Enterprise Value/Ebitda-5.85
Forecast
1Y Price Target
$46.40Price Target Upside121.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$4.82M
Bulls Say, Bears Say
Bulls Say
Phase 3 VITESSE / BLA PlanPositive Phase 3 topline and a stated plan to submit a BLA create a clear regulatory pathway toward approval. This materially de-risks the lead program, enhances the company's ability to secure partners or commercialization arrangements, and underpins potential future revenue streams and strategic optionality.
Low Leverage / No DebtA near-zero debt profile gives the company financial flexibility to continue R&D and regulatory activities without immediate interest burden. Low leverage reduces refinancing risk while the business is pre-revenue, improving resilience during lengthy clinical development and potential future commercialization phases.
Board Expertise AddedAdding an experienced industry executive to the board strengthens governance and strategic capabilities as the company prepares for potential regulatory submission and commercialization. Improved strategic oversight can aid partner negotiations, trial execution, and launch planning over the medium term.
Bears Say
Heavy Cash BurnSustained operating cash outflows near $100M annually imply ongoing reliance on external financing. Persistent burn elevates dilution and refinancing risk, constrains investment optionality, and could force unfavorable funding terms absent material partner deals or near-term regulatory milestones that justify capital raises.
Minimal And Declining RevenueWith virtually no product revenue and a sharp decline in top-line activity, the company lacks operating cash generation to fund development. This entrenches dependence on equity, debt, or partnerships for runway and makes the business model contingent on successful clinical outcomes and subsequent commercialization.
Equity Erosion / Dilution HistoryMaterial decline in shareholders' equity over recent years signals repeated losses and likely dilution to finance operations. This reduces the balance-sheet cushion, heightens funding vulnerability, and indicates future financing could further dilute holders if approval or partnership milestones are delayed.
DBV Technologies SA - American News
DBVT FAQ
What was DBV Technologies SA - American’s price range in the past 12 months?
DBV Technologies SA - American lowest stock price was $3.82 and its highest was $26.18 in the past 12 months.
What is DBV Technologies SA - American’s market cap?
DBV Technologies SA - American’s market cap is $1.18B.
When is DBV Technologies SA - American’s upcoming earnings report date?
DBV Technologies SA - American’s upcoming earnings report date is Mar 05, 2026 which is in 2 days.
How were DBV Technologies SA - American’s earnings last quarter?
DBV Technologies SA - American released its earnings results on Oct 28, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.318 by $0.078.
Is DBV Technologies SA - American overvalued?
According to Wall Street analysts DBV Technologies SA - American’s price is currently Undervalued.
Does DBV Technologies SA - American pay dividends?
DBV Technologies SA - American does not currently pay dividends.
What is DBV Technologies SA - American’s EPS estimate?
DBV Technologies SA - American’s EPS estimate is -0.19.
How many shares outstanding does DBV Technologies SA - American have?
DBV Technologies SA - American has 55,670,418 shares outstanding.
What happened to DBV Technologies SA - American’s price movement after its last earnings report?
DBV Technologies SA - American reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.318. Following the earnings report the stock price went down -2.186%.
Which hedge fund is a major shareholder of DBV Technologies SA - American?
Currently, no hedge funds are holding shares in DBVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DBV Technologies SA - American Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.40 (121.06% Upside)
$46.40 (121.06% Upside)
Blogger Sentiment
Bearish
DBVT Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $15.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
399.76%
12-Months-Change
Fundamentals
Return on Equity
-234.64%
Trailing 12-Months
Asset Growth
18.74%
Trailing 12-Months
Company Description
DBV Technologies SA - American
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
DBVT Stock 12 Month Forecast
Average Price Target
$46.40
▲(121.06% Upside)
Technical Analysis
Larimar Therapeutics
―
Korro Bio
―
4D Molecular Therapeutics
―
PureTech Health
―
Lexeo Therapeutics, Inc.
―